Courtney D. DiNardo
Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia.
Overview
Courtney DiNardo was principal investigator of VIALE-A, which showed venetoclax plus azacitidine improves survival and doubles remission rates in older adults with AML unfit for intensive chemotherapy, replacing hypomethylating agents alone and reshaping AML treatment globally. She led the first-in-human ivosidenib trial and co-led AGILE (ivosidenib plus azacitidine in IDH1-mutant AML). Her work continues on venetoclax-based triplets and measurable residual disease.
AGILE showed that for the roughly 6-10% of AML patients with an IDH1 mutation, a targeted doublet produces survival in the range of two years, an outcome previously unimaginable in unfit patients. Ivosidenib-azacitidine is approved and is one option alongside venetoclax-azacitidine for these patients. Which regimen, or triplet, is best for IDH1-mutated disease has not been settled by a randomised trial.
VIALE-A turned a palliative regimen into one that produces remission in two-thirds of older AML patients and is now the reference treatment for anyone not fit for intensive chemotherapy. It shifted the field towards lower-intensity targeted combinations and opened the door to adding FLT3, IDH and menin inhibitors to the backbone. Cure remains uncommon and most patients relapse within two years.
Pages like this
not linked directly; found by shared links- PersonAndrew H. Wei
Shares BCL-2, Venetoclax, Acute myeloid leukaemia and the tags aml, venetoclax.
- PairingVenetoclax + hypomethylating agent
Shares VIALE-A, VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Venetoclax, Acute myeloid leukaemia.
- PersonJohn F. Seymour
Shares BCL-2, Venetoclax and the tag venetoclax.
- PersonBarbara Eichhorst
Shares BCL-2, Venetoclax and the tag venetoclax.
- PersonKirsten Fischer
Shares BCL-2, Venetoclax and the tag venetoclax.
- IdeaShorter venetoclax courses in unfit AML
Shares VIALE-A, Venetoclax, Acute myeloid leukaemia.
- PersonGhayas C. Issa
Shares MD Anderson Cancer Center, Acute myeloid leukaemia and the tag aml.
- PersonWilliam G. Wierda
Shares BCL-2, Venetoclax, MD Anderson Cancer Center.